ANDA 212483, held by Fresenius Kabi USA. Foscarnet Sodium.
As of Nov 16, 2026, ANDA 212483 (Foscarnet Sodium), held by Fresenius Kabi USA, was first approved by FDA on Jan 29, 2021, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 29, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Foscarnet Sodium6GM/250ML (24MG/ML) ยท solution;intravenous | Foscarnet Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters